Translational Research Center for Expedite Novel Therapies in Cystic Fibrosis

囊性纤维化加速新疗法转化研究中心

基本信息

批准号：
8107664
负责人：
Everett P Greenberg
金额：
$ 96.42万
依托单位：
SEATTLE CHILDREN'S HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-07-06 至 2015-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8107664
关键词：
Anti-Inflammatory Agents Anti-inflammatory Area Bacterial Infections Basic Science Biliary cirrhosis Biological Assay Biological Markers Biology Biomedical Research Breathing Center Core Grants Center for Translational Science Activities Characteristics Child Chronic Chronic lung disease Clinical Clinical Investigator Clinical Research Clinical and Translational Science Awards Collaborations Collection Complication Cystic Fibrosis Cystic Fibrosis Transmembrane Conductance Regulator DNA Data Databases Development Development Plans Diagnostic Direct Costs Disease Drug Delivery Systems Epithelial Focus Groups Fostering Foundations Funding Gallium Genomics Goals Health Hepatobiliary Housing Human Ibuprofen Immune response Immunity Individual Infection Infection prevention Inflammation Inflammatory Response Informatics Institution Intravenous Laboratories Laboratory Finding Leadership Link Lung Medicine Microbiology Mucous Membrane National Institute of Diabetes and Digestive and Kidney Diseases Natural History Outcome Outcome Measure Pathogenesis Pediatrics Pharmaceutical Preparations Process Prognostic Marker Progressive Disease Proteomics Pseudomonas aeruginosa Pulmonary Cystic Fibrosis Recording of previous events Research Research Infrastructure Research Institute Research Personnel Resources Role Safety Sampling Screening procedure Senior Scientist Serum Specimen System Testing Therapeutic Time Tobramycin Translational Research Translations United States National Institutes of Health Universities Washington antimicrobial base biobank clinical efficacy cystic fibrosis patients improved medical schools novel novel therapeutic intervention pathogen pre-clinical programs ranpirnase repository therapeutic development

项目摘要

DESCRIPTION, OVERALL (provided by applicant): This P30 Cystic Fibrosis (CF) Research and Translational Core Center (CFRTC) will be located at the University of Washington School of Medicine (UWSOM) and its affiliated institution, Seattle Children's Research Institute (SCRI). This proposed P30 center program will enhance an existing robust basic and clinical research base at these institutions totally over $20 million direct costs in external NIH and Cystic Fibrosis Foundation funding ($15 million clinical based, $6 million laboratory based) and including 31 UWSOM investigators in 7 departments and/or divisions. The UWSOM has a long history of excellence in CF related translational research as evidenced by successful development of inhaled tobramycin (TOBI(r)) and leadership in the CFF supported Therapeutics Development Network. The research for this P30 will focus on four emphasis areas: 1) provide resources and expertise to expedite promising new therapeutic approaches to correct absent or dysfunctional CFTR and its secondary consequences, 2) foster sharing of existing and expanding human and bacterial biorepositories to enhance development of new biomarkers and laboratory assays, 3) enhance understanding of bacterial pathogenesis in CF lung disease, and 4) enhance understanding of host inflammatory response and its secondary consequences in CF. The center will be led by co-PI's, Dr. Bonnie Ramsey and Dr. E. Peter Greenberg, CF investigators both nationally recognized in their respective areas of clinical research and bacterial pathogenesis. They will be supported by other core leaders: Dr. William Parks, a senior investigator in modulation of immunity of epithelial mucosa and Dr. Samuel Miller, a senior scientist in bacterial genomics and proteomics. The center will consist of an Administrative Core (Ramsey and Greenberg) and four biomedical cores, Microbiology (Greenberg, Director), Genomics (Miller, Director), Inflammation (Parks, Director) and Clinical Translational (Ramsey, Director). The core centers will operate a Pilot and Feasibility (P&F) program led by Drs. Colin Manoil, a bacterial geneticist, and Ronald Gibson, a CF clinical investigator. Three P&F projects are included in the current proposal chosen through a competitive process from nine applications. During the funding period, the core center will focus on development of several novel therapeutic approaches to improve overall health for patients with CF.

描述，总体（由申请人提供）：此P30囊性纤维化（CF）研究与转化核心中心（CFRTC）将位于华盛顿大学医学院（UWSOM）及其附属机构西雅图儿童研究所（SCRI）。该拟议的P30中心计划将在这些机构的外部NIH和囊性纤维化基金会资金（1500万美元基于临床，600万美元的实验室）中，在这些机构的直接成本超过2000万美元的直接成本中，增强现有的强大基础和临床研究基础，其中包括31名UWSOM调查人员部门和/或部门。 UWSOM在CF相关的转化研究方面具有悠久的卓越历史，这是通过吸入毒素（TOBI（R））和CFF支持的Therapeutics开发网络中的领导力的成功开发所证明的。该P30的研究将重点关注四个重点领域：1）提供资源和专业知识，以加快有希望的新的治疗方法，以纠正缺乏或功能失调的CFTR及其次要后果，2）促进现有和扩展的人类和细菌生物疗法以增强现有的和扩展新的生物标志物和实验室测定，3）增强对CF肺部疾病细菌发病机理的了解，以及4）增强对宿主炎症反应及其在CF中的次要后果的了解。该中心将由Co-Pi的Bonnie Ramsey博士和E. Peter Greenberg博士领导，CF调查人员均在各自的临床研究和细菌发病机理领域都认可。他们将得到其他核心领导者的支持：威廉·帕克斯（William Parks）博士是调节上皮粘膜免疫力的高级研究员和细菌基因组学和蛋白质组学的高级科学家塞缪尔·米勒（Samuel Miller）博士。该中心将由行政核心（Ramsey和Greenberg）和四个生物医学核心，微生物学（Greenberg，董事），基因组学（Miller，董事），炎症（PARKS，董事）和临床翻译（Ramsey，董事）。核心中心将运营由DRS领导的飞行员和可行性（P＆F）计划。细菌遗传学家Colin Manoil和CF临床研究者Ronald Gibson。通过从九个申请。在资金期间，核心中心将重点放在开发几本小说治疗方法可改善CF患者的整体健康状况。